semaglutide mash approval πExciting news that is now FDA approved for (aka fatty liver disease) βAt week 72, the primary efficacy endpoint was based on histology (liver biopsy results). Interim results showed 63% GLP-1 BREAKTHROUGH: FDA APPROVES TREATMENT
Description
A good chunk of it is buried in the suprapubic fat pad a layer of fat above the base of the penis
Feriz-Bonelo, Erica Yama-Mosquera, Alex H
14 When sitagliptin and metformin are administered in combination, the most common adverse effects reported in 5% of patients or more include diarrhea, upper respiratory infection, and headache
Accessed July 1, 2026
One Low Price
